Effective inactivation of Nipah virus in serum samples for safe processing in low-containment laboratories

Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information o...

Full description

Saved in:
Bibliographic Details
Published inVirology journal Vol. 17; no. 1; p. 151
Main Authors Watanabe, Shumpei, Fukushi, Shuetsu, Harada, Toshihiko, Shimojima, Masayuki, Yoshikawa, Tomoki, Kurosu, Takeshi, Kaku, Yoshihiro, Morikawa, Shigeru, Saijo, Masayuki
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 09.10.2020
BioMed Central
BMC
Subjects
Aluminum
Aluminum foil
Biosafety
Biosafety level 4
blood serum
Diagnosis
diagnostic techniques
Disease
Disease control
Encephalitis
Epidemics
heat
humans
Infectivity
Laboratories
Lung diseases
Mortality
Nipah henipavirus
Nipah virus
pathogenicity
Respiratory diseases
respiratory tract diseases
Respirovirus
serodiagnosis
Serology
Ultraviolet radiation
Viral diseases
virology
Virus diseases
Virus inactivation
Virus stability
Viruses
Zoonoses
Japan
Malaysia
Singapore
Nipah virus
Biosafety level 4
Diagnosis
Virus inactivation
Virus stability
Online AccessGet full text

Cover

Abstract Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min. With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 10 TCID ) was completely inactivated. We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
AbstractList Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis.BACKGROUNDNipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis.We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min.METHODSWe determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min.With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 105 TCID50) was completely inactivated.RESULTSWith an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 105 TCID50) was completely inactivated.We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.CONCLUSIONSWe developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
BACKGROUND: Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. METHODS: We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min. RESULTS: With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 10⁵ TCID₅₀) was completely inactivated. CONCLUSIONS: We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 [degrees]C for 30 min. With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 x 10.sup.5 TCID.sub.50) was completely inactivated. We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
Background Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. Methods We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 [degrees]C for 30 min. Results With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 x 10.sup.5 TCID.sub.50) was completely inactivated. Conclusions We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility. Keywords: Nipah virus, Virus inactivation, Diagnosis, Biosafety level 4, Virus stability
Abstract Background Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. Methods We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min. Results With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 105 TCID50) was completely inactivated. Conclusions We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
Background Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. Methods We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min. Results With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 105 TCID50) was completely inactivated. Conclusions We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During large outbreaks of the viral disease, serological testing of serum samples could be a useful diagnostic tool, which could provide information on not only the diagnosis of NiV disease but also the history of an individual with previous exposure to the virus, thereby supporting disease control. Therefore, an efficient method for the inactivation of NiV in serum samples is required for serological diagnosis. We determined the optimal conditions for the inactivation of NiV infectivity in human serum using heating and UV treatment. The inactivation method comprised UV irradiation with a cover of aluminum foil for 30 min and heating at 56 °C for 30 min. With an optimized protocol for virus inactivation, NiV infectivity in serum samples (containing 6.0 × 10 TCID ) was completely inactivated. We developed a recommended protocol for the effective inactivation of NiV. This protocol would enable a regional or local laboratory to safely transport or process samples, including NiV, for serological testing in its biosafety level-2 facility.
ArticleNumber 151
Audience Academic
Author Morikawa, Shigeru
Shimojima, Masayuki
Saijo, Masayuki
Kaku, Yoshihiro
Watanabe, Shumpei
Fukushi, Shuetsu
Harada, Toshihiko
Yoshikawa, Tomoki
Kurosu, Takeshi
Author_xml – sequence: 1
  givenname: Shumpei
  surname: Watanabe
  fullname: Watanabe, Shumpei
– sequence: 2
  givenname: Shuetsu
  surname: Fukushi
  fullname: Fukushi, Shuetsu
– sequence: 3
  givenname: Toshihiko
  surname: Harada
  fullname: Harada, Toshihiko
– sequence: 4
  givenname: Masayuki
  surname: Shimojima
  fullname: Shimojima, Masayuki
– sequence: 5
  givenname: Tomoki
  surname: Yoshikawa
  fullname: Yoshikawa, Tomoki
– sequence: 6
  givenname: Takeshi
  surname: Kurosu
  fullname: Kurosu, Takeshi
– sequence: 7
  givenname: Yoshihiro
  surname: Kaku
  fullname: Kaku, Yoshihiro
– sequence: 8
  givenname: Shigeru
  surname: Morikawa
  fullname: Morikawa, Shigeru
– sequence: 9
  givenname: Masayuki
  surname: Saijo
  fullname: Saijo, Masayuki
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33036623$$D View this record in MEDLINE/PubMed
BookMark eNqFkktv1DAUhSNURB_wB1igSGxgkeJ37A1SVRWoVIHEQ2JnOc711KPEHuxkgH-PZ6aUToVAWeTK_s6R773nuDoIMUBVPcXoFGMpXmVMlOQNIqhBmBHeyAfVEW4ZbRghXw_u1IfVcc5LhCgRrXpUHVKKqBCEHlXLC-fATn4NtQ9mU5jJx1BHV7_3K3Ndr32ac7mrM6R5rLMZVwPk2sVUagf1KkULOfuw2EBD_N7YGCbjwwhhqgfTxWSmmDzkx9VDZ4YMT27-J9WXNxefz981Vx_eXp6fXTVWUDQ1HCRVljBqe8ydoJw7YxClqseWsU52CloDzrAOc2Uxc23bCSm7zkJLpGH0pLrc-fbRLPUq-dGknzoar7cHMS20SZO3A-gedUYgLqR1jGHZdz30VAmH2laA6Enxer3zWs3dCL0tPSUz7Jnu3wR_rRdxrVvOWk5oMXhxY5DitxnypEefLQyDCRDnrAkvO2KCcPR_lDGluBJCFfT5PXQZ5xTKVAvFsaJEtvwPtTClVx9cLE-0G1N9JqhkQjC8afH0L1T5ehh92SU4X873BC_3BJt9w49pYeac9eWnj_vss7vzux3c7wAWgOwAm2LOCdwtgpHepFzvUq5LyvU25VoWkbwnsn7a5rY83Q__kv4CmsMAPg
CitedBy_id crossref_primary_10_1371_journal_pntd_0010157
crossref_primary_10_3390_ijms23137246
crossref_primary_10_1080_14737159_2024_2368591
crossref_primary_10_3390_v14051052
crossref_primary_10_1016_j_vacune_2024_05_014
crossref_primary_10_3390_v14092057
crossref_primary_10_1016_S1473_3099_24_00262_7
crossref_primary_10_1038_s41598_022_15228_0
crossref_primary_10_1016_j_vacun_2024_02_002
crossref_primary_10_3390_pathogens12070952
crossref_primary_10_1371_journal_pntd_0011851
Cites_doi 10.3201/eid2207.160233
10.4269/ajtmh.18-0937
10.3201/eid1307.061128
10.1007/s00705-019-04247-4
10.1016/j.jviromet.2017.09.020
10.3201/eid1803.111121
10.1016/j.virusres.2007.11.010
10.1016/j.jviromet.2016.04.004
10.1128/JCM.20.3.486-489.1984
10.1016/j.jobb.2020.02.002
10.1016/j.jphotobiol.2008.10.009
10.1016/j.virol.2014.09.003
10.1086/647951
10.1016/j.antiviral.2018.09.009
10.3201/eid2506.181620
10.1089/vim.2008.0007
10.1016/j.jviromet.2019.03.009
10.3201/eid1107.041350
10.1016/j.jcpa.2007.03.002
10.1128/JCM.01449-15
10.1016/j.jviromet.2009.05.014
10.3201/eid1204.051181
10.1007/s00430-004-0219-0
10.1186/s12985-016-0510-x
10.1016/j.jviromet.2009.04.037
10.1016/j.jviromet.2011.11.003
10.1016/0166-0934(88)90099-7
10.1089/vbz.2015.1795
10.1038/srep30916
10.3855/jidc.3648
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
NPM
ISR
3V.
7U9
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOA
DOI 10.1186/s12985-020-01425-8
DatabaseName CrossRef
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE - Academic
AGRICOLA




Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1743-422X
EndPage 151
ExternalDocumentID oai_doaj_org_article_d0ba60568cf4418dbded396f0776e6d2
PMC7547523
A638466412
33036623
10_1186_s12985_020_01425_8
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
Malaysia
Singapore
GeographicLocations_xml – name: Singapore
– name: Malaysia
– name: Japan
GrantInformation_xml – fundername: ;
  grantid: JP20fk0108080; 20wm0325002; 19fk0108072j0002; JP20fk0108080; JP20fk0108080
GroupedDBID ---
0R~
123
29Q
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAHBH
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ISR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
IFM
NPM
PMFND
7U9
7XB
8FK
AZQEC
COVID
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
7S9
L.6
5PM
PUEGO
ID FETCH-LOGICAL-c630t-5e839c243cd15f6355faa0339d1c44b8b9e7aefa4b159c14f77b688bbce728a43
IEDL.DBID M48
ISSN 1743-422X
IngestDate Wed Aug 27 00:41:37 EDT 2025
Thu Aug 21 18:25:37 EDT 2025
Fri Jul 11 09:49:40 EDT 2025
Fri Jul 11 12:00:50 EDT 2025
Fri Jul 25 22:36:33 EDT 2025
Tue Jun 17 21:38:43 EDT 2025
Tue Jun 10 20:30:39 EDT 2025
Fri Jun 27 04:25:30 EDT 2025
Thu Jan 02 22:56:50 EST 2025
Tue Jul 01 01:44:46 EDT 2025
Thu Apr 24 22:53:10 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Nipah virus
Biosafety level 4
Diagnosis
Virus inactivation
Virus stability
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c630t-5e839c243cd15f6355faa0339d1c44b8b9e7aefa4b159c14f77b688bbce728a43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12985-020-01425-8
PMID 33036623
PQID 2451932875
PQPubID 55248
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_d0ba60568cf4418dbded396f0776e6d2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7547523
proquest_miscellaneous_2574346250
proquest_miscellaneous_2449959669
proquest_journals_2451932875
gale_infotracmisc_A638466412
gale_infotracacademiconefile_A638466412
gale_incontextgauss_ISR_A638466412
pubmed_primary_33036623
crossref_primary_10_1186_s12985_020_01425_8
crossref_citationtrail_10_1186_s12985_020_01425_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-10-09
PublicationDateYYYYMMDD 2020-10-09
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-09
  day: 09
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Virology journal
PublicationTitleAlternate Virol J
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References KS Feldman (1425_CR32) 2009; 161
Y Kaku (1425_CR35) 2019; 269
SP Luby (1425_CR11) 2009; 49
JE Burton (1425_CR16) 2017; 250
CE Mire (1425_CR25) 2019; 25
CE Mire (1425_CR26) 2016; 6
O Escaffre (1425_CR13) 2013; 7
DA Satharasinghe (1425_CR31) 1907; 2016
DJ Middleton (1425_CR4) 2007; 136
LFMJ Wang (1425_CR9) 2013
JF Saluzzo (1425_CR24) 1988; 22
J Bartl (1425_CR15) 2004; 4
HF Rabenau (1425_CR23) 2005; 194
R Fogarty (1425_CR14) 2008; 132
Y Kaku (1425_CR33) 2012; 179
JT Roehrig (1425_CR19) 2008; 21
YJ Huang (1425_CR20) 2015; 15
SW Mitchell (1425_CR21) 1984; 20
SL Park (1425_CR22) 2016; 234
GK Amarasinghe (1425_CR1) 2019; 164
ES Park (1425_CR30) 2014; 468–470
MK Azar Daryany (1425_CR28) 2009; 94
E Haddock (1425_CR17) 2016; 22
Y Kaku (1425_CR34) 2009; 160
SP Luby (1425_CR3) 2012; 359
S Wacharapluesadee (1425_CR8) 2016; 13
BSP Ang (1425_CR2) 2018; 2018
SJ Smither (1425_CR18) 2015; 53
1425_CR27
I Sendow (1425_CR7) 2006; 12
JM Reynes (1425_CR6) 2005; 11
ES Gurley (1425_CR10) 2007; 13
F Feldmann (1425_CR29) 2019; 100
MS Mehand (1425_CR12) 2018; 159
F Hasebe (1425_CR5) 2012; 18
References_xml – volume: 359
  start-page: 25
  year: 2012
  ident: 1425_CR3
  publication-title: Curr Top Microbiol Immunol
– volume: 22
  start-page: 1292
  year: 2016
  ident: 1425_CR17
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2207.160233
– volume: 2018
  start-page: 56
  year: 2018
  ident: 1425_CR2
  publication-title: J Clin Microbiol
– volume: 100
  start-page: 1275
  year: 2019
  ident: 1425_CR29
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.18-0937
– volume: 13
  start-page: 1031
  year: 2007
  ident: 1425_CR10
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1307.061128
– volume: 164
  start-page: 1967
  year: 2019
  ident: 1425_CR1
  publication-title: Arch Virol
  doi: 10.1007/s00705-019-04247-4
– volume: 250
  start-page: 34
  year: 2017
  ident: 1425_CR16
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2017.09.020
– volume: 18
  start-page: 536
  year: 2012
  ident: 1425_CR5
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1803.111121
– volume: 132
  start-page: 140
  year: 2008
  ident: 1425_CR14
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2007.11.010
– volume: 234
  start-page: 152
  year: 2016
  ident: 1425_CR22
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2016.04.004
– volume: 20
  start-page: 486
  year: 1984
  ident: 1425_CR21
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.20.3.486-489.1984
– ident: 1425_CR27
  doi: 10.1016/j.jobb.2020.02.002
– volume: 94
  start-page: 120
  year: 2009
  ident: 1425_CR28
  publication-title: J Photochem Photobiol B
  doi: 10.1016/j.jphotobiol.2008.10.009
– volume: 468–470
  start-page: 524
  year: 2014
  ident: 1425_CR30
  publication-title: Virology
  doi: 10.1016/j.virol.2014.09.003
– volume: 49
  start-page: 1743
  year: 2009
  ident: 1425_CR11
  publication-title: Clin Infect Dis
  doi: 10.1086/647951
– volume: 159
  start-page: 63
  year: 2018
  ident: 1425_CR12
  publication-title: Antiviral Res
  doi: 10.1016/j.antiviral.2018.09.009
– volume: 25
  start-page: 1144
  year: 2019
  ident: 1425_CR25
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2506.181620
– volume: 21
  start-page: 123
  year: 2008
  ident: 1425_CR19
  publication-title: Viral Immunol
  doi: 10.1089/vim.2008.0007
– volume: 269
  start-page: 83
  year: 2019
  ident: 1425_CR35
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2019.03.009
– volume: 11
  start-page: 1042
  year: 2005
  ident: 1425_CR6
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1107.041350
– volume: 136
  start-page: 266
  year: 2007
  ident: 1425_CR4
  publication-title: J Comp Pathol
  doi: 10.1016/j.jcpa.2007.03.002
– volume: 53
  start-page: 3148
  year: 2015
  ident: 1425_CR18
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01449-15
– volume: 161
  start-page: 52
  issue: 1
  year: 2009
  ident: 1425_CR32
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2009.05.014
– volume: 12
  start-page: 711
  year: 2006
  ident: 1425_CR7
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1204.051181
– volume: 194
  start-page: 1
  year: 2005
  ident: 1425_CR23
  publication-title: Med Microbiol Immunol
  doi: 10.1007/s00430-004-0219-0
– volume: 13
  start-page: 53
  year: 2016
  ident: 1425_CR8
  publication-title: Virol J
  doi: 10.1186/s12985-016-0510-x
– volume: 2016
  start-page: 7
  year: 1907
  ident: 1425_CR31
  publication-title: Front Microbiol
– volume: 160
  start-page: 7
  year: 2009
  ident: 1425_CR34
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2009.04.037
– volume: 179
  start-page: 226
  year: 2012
  ident: 1425_CR33
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2011.11.003
– volume: 4
  start-page: 6
  year: 2004
  ident: 1425_CR15
  publication-title: Meas Sci Rev
– volume: 22
  start-page: 165
  year: 1988
  ident: 1425_CR24
  publication-title: J Virol Methods
  doi: 10.1016/0166-0934(88)90099-7
– start-page: 286
  volume-title: Fields virology
  year: 2013
  ident: 1425_CR9
– volume: 15
  start-page: 674
  year: 2015
  ident: 1425_CR20
  publication-title: Vector Borne Zoonotic Dis
  doi: 10.1089/vbz.2015.1795
– volume: 6
  start-page: 30916
  year: 2016
  ident: 1425_CR26
  publication-title: Sci Rep
  doi: 10.1038/srep30916
– volume: 7
  start-page: 308
  year: 2013
  ident: 1425_CR13
  publication-title: J Infect Dev Ctries
  doi: 10.3855/jidc.3648
SSID ssj0032679
Score 2.3210287
Snippet Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in humans. During...
Background Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in...
BACKGROUND: Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate in...
Abstract Background Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes severe encephalitis and respiratory disease with a high mortality rate...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 151
SubjectTerms Aluminum
Aluminum foil
Biosafety
Biosafety level 4
blood serum
Diagnosis
diagnostic techniques
Disease
Disease control
Encephalitis
Epidemics
heat
humans
Infectivity
Laboratories
Lung diseases
Mortality
Nipah henipavirus
Nipah virus
pathogenicity
Respiratory diseases
respiratory tract diseases
Respirovirus
serodiagnosis
Serology
Ultraviolet radiation
Viral diseases
virology
Virus diseases
Virus inactivation
Virus stability
Viruses
Zoonoses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF-koPgiWr9iq6wi-CChSXaz2X2sYqlC-6AW-rbsp71Sk6O5WPzvncnmjgtCffHtyE4gNzM785tk5reEvJWxwSEZl9cSR3IKX-QyKJ5zFQyLUJCJiMPJJ6fi-Ix_Oa_Pt476wp6wRA-cFHfgC2sAcgvpImRu6a0PnikRkYYmCD9GX8h562IqxWDAJI1aj8hIcdBDVpM4iYxNWOCluZyloZGt_--YvJWU5g2TWxno6CF5MEFHepge-RG5E9pdcjcdJvl7l9w7mT6TPyaXiZMYAhldtDi5kN670i7S08XSXNBfi-uhhzUKDjj8pL1BjuCeAoCF3zHQZRofgLSGQlfdTY4t7VPrAJ0cp8Mq-wk5O_r0_eNxPh2qkDvBilVeB4BEruLM-bKOCDeiMQVjypeOcyutCo0J0XALQMeVPDaNFVJa60JTScPZU7LTdm14TqhStorCeYvfJi1nxnkoLn3NDGu4iXVGyrWOtZsYx_Hgiys9Vh5S6GQXDXbRo120zMj7zT3LxLdxq_QHNN1GErmyxwvgQXryIP0vD8rIGzS8RjaMFtttfpih7_Xnb1_1IUQn5N8vQejdJBQ7-A_OTNMLoAkk0JpJ7s8kYbu6-fLav_QULnpd8RFIQ-2YkdebZbwTW-Da0A0ow5EbTgh1i0wNgJBDSVtk5Fly2Y1uGIIVALsZaWbOPFPefKVdXIyE403Nm7piL_6HtvfI_Qr3IfZgqH2ys7oewkvAdSv7atzCfwDl30oA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9RAEF60ovgiWrVGq6wi-CChSXaz2TxJFUsV2ge1cG_L_mxPanK9XCr-984ke2eDcG9HdgK5ndnZb3ZnviHkrQwVFsnYtJRYkpO5LJW-5imvvWYBAjIRsDj55FQcn_Gvs3IWD9y6mFa59omDo3atxTPyg4IPWAPg9YfFVYpdo_B2NbbQuE3uIHUZWnU12wRcgEwGrj0E3Skvitm6aEaKgw72OYm1yZiWBXabysnGNPD3_--lb2xT0xTKG3vS0UPyIIJJejhq_xG55ZtdcndsL_lnl9w7iRfnj8nPkaUYXBudN1jLMJ7E0jbQ0_lCX9Dr-bLvYIyCSfa_aKeRNbijAGnhd_B0MRYUwEaHQpft7xST3GMyAY2m1GLc_YScHX3-8ek4jW0WUitYtkpLDyDJFpxZl5cBAUjQOmOsdrnl3EhT-0r7oLkB6GNzHqrKCCmNsb4qpObsKdlp2sY_I7SuTRGEdQZvKw1n2joIN13JNKu4DmVC8vUcKxs5yLEVxqUaYhEp1KgXBXpRg16UTMj7zTuLkYFjq_RHVN1GEtmzhwft8lzFxahcZjSEcULaAGhQOuO8Y7UISG3khSsS8gYVr5Afo8EEnHPdd5368v2bOgR_hYz8OQi9i0Khhf9gdaxngJlASq2J5P5EEhawnQ6v7UtFB9Kpf-aekNebYXwTk-Ia3_Yow5EtToh6i0wJxs8hyM0Ssjea7GZuGMIXgL8JqSbGPJm86UgzvxgoyKuSV2XBnm__9BfkfoErDPMt6n2ys1r2_iVguJV5NSzUv6cJQv8
  priority: 102
  providerName: ProQuest
Title Effective inactivation of Nipah virus in serum samples for safe processing in low-containment laboratories
URI https://www.ncbi.nlm.nih.gov/pubmed/33036623
https://www.proquest.com/docview/2451932875
https://www.proquest.com/docview/2449959669
https://www.proquest.com/docview/2574346250
https://pubmed.ncbi.nlm.nih.gov/PMC7547523
https://doaj.org/article/d0ba60568cf4418dbded396f0776e6d2
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF71IRAXBOVlKJFBSByQwfGud9cHhFrUqiAlQoVIva322QYFO8QJ0H_PjO1Etah64hZ5x4fMzux84535hpBXMghskrFJLrElJ3VpIn3BElZ4TQMkZDxgc_JozE8m7PNZfrZF1uOOOgXW16Z2OE9qspi9_fPz8gM4_PvG4SV_V0PMkthnjCVWYIOJ3Ca7EJkETjQYsc2tAiAVUawbZ659rxecGg7_f0_qK6GqX0Z5JS4d3yN3O0AZH7QWcJ9s-XKP3GpHTF7ukduj7vL8AfneMhXD8RZPS-xnaL_GxlWIx9O5voh_TRerGtZiMMvVj7jWyBxcxwBr4Xfw8bxtKoBgh0Kz6neChe5dQUHcmVOFufdDMjk--vbxJOlGLSSW03SZ5B6Aks0YtW6YBwQhQeuU0sINLWNGmsIL7YNmBuCPHbIghOFSGmO9yKRm9BHZKavSPyFxUZgscOsM3lgaRrV1kHK6nGoqmA55RIZrHSvb8ZDjOIyZavIRyVW7Lwr2RTX7omRE3mzembcsHDdKH-LWbSSRQbt5UC3OVeeQyqVGQyrHpQ2ACKUzzjta8ID0Rp67LCIvceMVcmSUWIRzrld1rT59PVUHcGYhK_8QhF53QqGC_2B119MAmkBarZ7kfk8SnNj2l9f2pdY-oDLWwGvIKCPyYrOMb2JhXOmrFcowZIzjvLhBJgeYyCDRTSPyuDXZjW4oQhiAwBERPWPuKa-_Uk4vGhpykTORZ_Tp_9D2M3InQz_Eyoxin-wsFyv_HNDe0gzItjgTA7J7eDT-cjpovpkMGrf-C3zsVOE
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIh4XBOVlKLAgEIfKquNdr9cHhMqjSmiTA7RSbst6H21QsUOcUPVP8RuZsZ1QCym33iLv2Ip33t6Zbwh5LX2KTTImTCS25EQ2CqXLeMgzp5mHhEx4bE4ejkT_mH8ZJ-MN8mfZC4NllUubWBtqWxr8Rr4b8zrWgPD6_fRXiFOj8HR1OUKjEYsDd3EOKVv1bvAJ-Psmjvc_H33sh-1UgdAIFs3DxEFMYGLOjO0lHv2t1zpiLLM9w3ku88yl2nnNc_D0psd9muZCyjw3Lo2l5gyee41cB8cbYbKXjlcJHkRCNbYfBvkhj-PxsklHit0K_KrEXmgsAwM9CWXHEdbzAv73CpfcYrdk85IP3L9L7rTBK91rpO0e2XDFFrnRjLO82CI3h-1B_X3yo0FFBlNKJwX2TjRffmnp6Wgy1af092S2qGCNggosftJKI0pxRSGEht_e0WnTwACOFYnOyvMQi-rb4gXaim6Jef4DcnwlDHhINouycI8JzbI89sLYHE9Hc860sZDe2oRplnLtk4D0lnusTIt5jqM3zlSd-0ihGr4o4Iuq-aJkQHZW90wbxI-11B-QdStKROuuL5SzE9Uqv7JRriFtFNJ4iD6lza2zLBMeoZScsHFAXiHjFeJxFFjwc6IXVaUG376qPbCPOAGgB0RvWyJfwjsY3fZPwE4ghFeHcrtDCQbDdJeX8qVag1Wpf-oVkJerZbwTi_AKVy6QhiM6nRDZGpoEhJ9DUh0F5FEjsqu9YRguQbgdkLQjzJ3N664Uk9Ma8jxNeJrE7Mn6v_6C3OofDQ_V4WB08JTcjlHbsNYj2yab89nCPYP4cZ4_r5WWku9XbSX-AqqQgG4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effective+inactivation+of+Nipah+virus+in+serum+samples+for+safe+processing+in+low-containment+laboratories&rft.jtitle=Virology+journal&rft.au=Shumpei+Watanabe&rft.au=Shuetsu+Fukushi&rft.au=Toshihiko+Harada&rft.au=Masayuki+Shimojima&rft.date=2020-10-09&rft.pub=BMC&rft.eissn=1743-422X&rft.volume=17&rft.issue=1&rft.spage=1&rft.epage=8&rft_id=info:doi/10.1186%2Fs12985-020-01425-8&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d0ba60568cf4418dbded396f0776e6d2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-422X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-422X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-422X&client=summon